The partnership will work to develop first-in-class, small molecule, protein-protein interaction antagonists (PPIAs) against a protein that causes cancer cell invasion
The partnership will develop first-in-class, small molecule, PPIAs against a protein that causes cancer cell invasion. (Credit: mwooten from Pixabay)
Eurofins Discovery, a subsidiary of Eurofins Scientific, has partnered with Switzerland-based biotechnology firm Invasight to develop therapeutics in the fight against cancer.
The partnership will work to develop first-in-class, small molecule, protein-protein interaction antagonists (PPIAs) against a protein that causes cancer cell invasion.
Swiss Invasight is collaborating with Eurofins Discovery’s DiscoveryOne, which is an integrated drug discovery platform that offers professional thorough support to advance programmes from concept to preclinical development and beyond.
DiscoveryOne is said to have capabilities like medicinal chemistry, in vitro pharmacology, ADME-PK, biomarkers and industry-leading safety pharmacology.
To advance to a development candidate, Invasight will integrate Eurofins Discovery’s fully integrated capabilities with its own ACINDA (Anti-cancer Cell Invasion Drug Discovery Accelerator) technology.
Eurofins said that the breakthrough ACINDA technology closely mimics the in vivo tumour microenvironment. It precisely designs the small molecule inhibitors against proteins that cause cancer cell invasion.
The partnership will combine the DiscoveryOne team’s track record and experience in moving candidates effectively from hit to the preclinical candidate with Invasight’s proprietary cancer cell invasion models.
Both firms anticipate that high-quality molecules will advance quickly to IND-enabling studies, accelerating therapeutics in the fight against cancer.
Eurofins Discovery offers a diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling to drug discovery researchers. It has a broad portfolio of around 3,500 drug discovery services and 1,800 products.
The company offers in vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities.
In February last year, Eurofins Clinical Testing, another subsidiary of Eurofins Scientific, acquired Vietnam-based Genetic Testing Service JSC (Gentis).
Gentis is a genetic testing company that makes technological advancements in DNA testing accessible and affordable. It offers specialised DNA testing services like obstetrical genetics, genealogical DNA tests, oncology, and Covid-19 testing services.